The Lixisenatide Trial

The Lixisenatide Trial
Another trial in the promising GLP-1 receptor agonist cohort and co-funded by The Cure Parkinson's Trust and the Van Andel Institute through the Linked Clinical Trials initiative, this study will evaluate the effect of the diabetic drug lixisenatide versus placebo on the progression of motor disability in people with early Parkinson's in order to assess its potential disease-modifying effect. The ... read more
Source: Published on 2018-07-18